Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Allogeneic, BCMA, CAR-T Nov 13 | 2023Roche Collaboration Milestones and Payments Accelerated; P-MUC1C-ALLO1's Clinical Update Postponed to H1 2024; Poseida’s Q3 2023 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Nov 10 | 2023Breyanzi sBLA for R/R CLL/SLL Receives FDA Priority ReviewAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 10 | 2023Abecma T2V Receives a Second RSI; When Could Abecma and Carvykti Receive a Positive CHMP Opinion? November CHMP HighlightsAccess Free BlastFree
Posted in: Allogeneic, Autologous, TCR, Topics Nov 09 | 2023Afami-cel BLA Submission on Track for YE 2023, Lete-cel IND Set to Transition from GSK by YE 2023; MSLN TRuC Programs Deprioritized; Adaptimmune to Advance PRAME Program to the Clinic in 2024; Adaptimmune’s Q3 2023 Earnings CallAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Nov 08 | 2023Gilead’s Cell Therapy Revenue Continues to Grow; Promising Results from CART-ddBCMA Expected at ASH 2023; Gilead’s Q3 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19, Topics Nov 08 | 2023Cellectis to Present Updated Clinical Data at ASH 2023; Caribou Still Plans to Share FDA Feedback on CB-010’s Pivotal Trial in 2L LBCL by YE 2023; Cellectis and Caribou Q3 2023 Earnings SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Nov 07 | 2023Lyell and CRISPR Tx Present Novel CAR-Ts in Solid Tumors; SITC 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Nov 06 | 2023Carisma Tx Shows Initial Results from its Collaboration with Moderna; AstraZeneca Presents AZD6422’s Preclinical Development in Gastrointestinal Cancers and a Synergistic Combination of AZD074 with Enzalutamide in Prostate Cancer; SITC 2023 Analysis 1Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 06 | 2023Could Abecma Receive a CHMP Positive Opinion this Week?; November’s CHMP AgendaAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Nov 03 | 2023ALLO-501A’s ALPHA2 Trial Expands to Europe and Australia; EXPAND Study to Open Enrollment in Europe; ALLO-316’s Initial Results Postponed to Early 2024; Allogene’s Q3 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, TCR Nov 03 | 2023Adaptimmune Presents Positive Lete-cel and Afami-cel Data in SS and MRCLSAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19, Topics Nov 03 | 2023Obe-cel BLA Submission Remains on Track for YE 2023; YTB323 and Obe-cel to Compete on Safety in SLE; AUTO6NG’s Trial in Neuroblastoma to Be Initiated by YE 2023; Clinical Results of AUTO8 at ASH; Autolus’s Q3 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T Nov 02 | 2023Kite to Collaborate with Epic Bio to Develop New Therapies for CancerAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD123, CD22, Dual/triple agonist Nov 02 | 2023AstraZeneca and Cellectis Enter into Collaboration to Develop up to 10 Novel Cell and Gene Therapy Candidates Leveraging Cellectis’s Gene Editing Technologies and Manufacturing CapabilitiesAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Oct 31 | 2023An ARI-0003 Trial to Be Initiated by Hospital Clinic; Mustang’s MB-109 Receives IND Clearance from the FDAAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Oct 27 | 2023BMS’s Cell Therapy Franchise Sales Decrease; KarMMa-9 Initiated; The FDA Clears BMS-986353’s IND in MS; First Patients in SLE Trial Dosed; BMS’s Q3 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 26 | 2023Obe-cel Trial in SLE on Track to Be Initiated in Early 2024; Obe-cel’s Development in Oncology Could Accelerate its Path to Market in SLE; Autolus to Leverage Infrastructure Established for ALL in Autoimmune DiseasesAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 25 | 2023Kymriah's Revenue Continues to Decrease; No Updates on Cell Therapy Programs; Novartis’s Q3 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, TCR Oct 25 | 2023ADP-A2M4CD8 Maintains its Efficacy in MAGE-A4+ Solid Tumors; BNT211 Continues to Impress in Solid Tumors; IM96 Demonstrates Excellent Safety Profile but Modest Preliminary Efficacy in mCRC; ESMO 2023 Analysis 2Access Free BlastFree
Posted in: Autologous, CD19 Oct 23 | 2023Comparative Analyses Suggest Yescarta is More Effective than Epkinly and Columvi but Less Safe; ESMO 2023 Analysis 1Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.